Latest Pharma and Biotech News
Pharmaceutical
5 June 2025 Bayer’s USA-based subsidiary Vividion Therapeutics has taken over full development and commercialization rights for VVD-214, a clinical-stage Werner helicase (WRN) inhibitor originally discovered under a research collaboration with Roche.
Today's issue
Refine Search
Pharmaceutical
US drugmaker Vertex Pharmaceutical (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and, in particular, its Alyftrek (vanzacaftor/tezacaftor/deutivacaftor). 7 June 2025
Pharmaceutical
In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%. 6 June 2025
Pharmaceutical
US cardiorenal-focussed drugmaker Ardelyx announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer. 6 June 2025
Biotechnology
Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III VALIANT study, investigating Aspaveli/Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 6 June 2025
Biotechnology
Japan’s Otsuka today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. 6 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Biotechnology
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the development of new drug therapy options to treat this disease, according to a report from DelveInsight. 6 June 2025
Biotechnology
Texas-based ImmunoPrecise Antibodies, a leader in AI-driven biotherapeutics, closed 22% higher Thursday. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Pharmaceutical
AstraZeneca has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, for adults newly diagnosed with chronic lymphocytic leukemia (CLL). 6 June 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of German pharma major Bayer’s Nubeqa (darolutamide) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). 6 June 2025
Biotechnology
US commercial-stage drugmaker Corcept Therapeutics has presented results from its DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) 2025 annual meeting. 6 June 2025
Biotechnology
US gene therapy company RegeNXBio yesterday announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, RegeNXBio’s potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy. 6 June 2025
Biotechnology
The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal cell carcinoma patients who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA). 5 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Biotechnology
German genetic medicine company ViGeneron has announced a rebrand to become VeonGen Therapeutics. 5 June 2025
Biotechnology
US rare disease meds developer Sarepta Therapeutics revealed that its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the US Food and Drug Administration. 5 June 2025
Biotechnology
AI-enabled biotech Juvenescence today announced the acquisition of Ro5 Inc, a proprietary AI drug discovery company. 5 June 2025
Biotechnology
US biopharma Cullinan Therapeutics has entered into an agreement with Genrix Bio for an all-indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T-cell engager for everywhere outside Greater China. 5 June 2025
All news
Biotechnology
US biopharma Novavax closed 20% higher on Wednesday after announcing an update on its COVID-19 vaccine. 24 April 2025
Biotechnology
Hong Kong-based biopharma company Akeso announced that its global first-in-class PD-1/VEGF bispecific antibody, ivonescimab, in combination with chemotherapy, has demonstrated strongly positive results in the Phase III clinical trial (AK112-306/HARMONi-6) for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC). 24 April 2025
Pharmaceutical
Denmark’s Zealand Pharma, a company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Utpal Singh as chief scientific officer. 24 April 2025
Pharmaceutical
UK-based pharma company Indivior saw it shares rose 5.3% to 738.50 pence in early trading today after it announced financial results for the three months ending March 31, 2025. 24 April 2025
Pharmaceutical
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment for patients aged 16 and over, in the UK for a rare neurodegenerative movement disorder called Friedreich’s ataxia (FA). 24 April 2025
Pharmaceutical
Drug distributors like Cardinal Health, Cencora and McKesson will play a key role in the drug supply chain, improving patient access to healthcare, according to Morningstar. 24 April 2025
Pharmaceutical
An Expert View from Omar Ali, head of payers, Verpora. 24 April 2025
Pharmaceutical
Shares in Eli Lilly shot up last Thursday after the US pharma major announced positive top-line Phase III results from ACHIEVE-1, comparing orforglipron to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. 23 April 2025
Pharmaceutical
Denmark-based allergy immunotherapy specialist ALK Abello today announced that its Itulazax (tree pollen sublingual allergy immunotherapy tablet) has been approved by the European regulator for treatment of young children and adolescents aged five to 17. 23 April 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja (leniolisib), from Dutch biopharma company Pharming, for reimbursement and use within the National Health Service (NHS) in England and Wales. 23 April 2025
Biotechnology
Autoimmune diseases specialist Immunovant has announced changes to its leadership team and the expanded development of its drug IMVT-1402 into two new indications, Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE). 23 April 2025
Biotechnology
Cambridge, USA-based biotech Repertoire Immune Medicines today announced a collaboration and license agreement with Genentech, a subsidiary of Swiss pharma giant Roche, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. 23 April 2025
Biotechnology
A new report highlights disparities in access to CAR T-cell therapies across Europe, with eligible patient treatment rates as low as 11% in some countries. The analysis suggests that complex care pathways and inconsistent funding models are key barriers to broader use of the treatment. 23 April 2025
Pharmaceutical
The Trump administration is reportedly revisiting a contentious drug pricing strategy that would tie US medicine prices to those paid in other developed nations, according to a Reuters report citing multiple industry sources. 23 April 2025
Biotechnology
South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna over key technologies used in the manufacture of mRNA vaccines. 23 April 2025
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim and Dutch precision oncology company Tessellate Bio have entered into a research collaboration and global license agreement. 23 April 2025
Biotechnology
Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp. 23 April 2025
Pharmaceutical
The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US President Donald Trump’s proposed pharmaceutical tariffs impacting global supply chains. 23 April 2025
Pharmaceutical
US pharma major Bristol Myers Squibb saw its shares fall 4% in after-hours trading on Tuesday, after it announced disappointing top-line results from the Phase III ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. 23 April 2025
Biotechnology
French drug developer Innate Pharma’s shares were up 5.6% at 1.81 euros in early trading after it announced a review of its January 2016 research collaboration and license agreement with Sanofi. 23 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze